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We previously developed an immunohistochemical method for estimating cell cycle state and phase in tissue samples, including
biopsies that are too small for flow cytometry. We have used our technique to examine whether primary abnormalities of the cell
cycle exist in laryngeal neoplasia. Antibodies against the markers of cell cycle entry, minichromosome maintenance protein-2 (Mcm-2)
and Ki67, and putative markers of cell cycle phase, cyclin D1 (G1-phase), cyclin A (S-phase), cyclin B1 (G2-phase) and
phosphohistone H3 (Mitosis) were applied to paraffin-embedded sections of normal larynx (n¼8), laryngeal dysplasia (n¼10) and
laryngeal squamous cell carcinoma (n¼10). Cells expressing each marker were determined as a percentage of total cells, termed the
labelling index (LI), and as a percentage of Mcm-2-positive cells, termed the labelling fraction (LF). The frequency of coexpression of
each putative phase marker was investigated by confocal microscopy. There was a correlation between Mcm-2 and Ki67 LIs
(r¼0.93) but Mcm-2 LIs were consistently higher. All cells expressing a phase marker coexpressed Mcm-2, whereas Ki67 was not
expressed in a proportion of these cells. The putative phase markers showed little coexpression. Labelling index values increased on
progression from normal larynx through laryngeal dysplasia to squamous cell carcinoma for Mcm-2 (P¼0.001), Ki67 (P¼0.0002),
cyclin D1 (P¼0.015), cyclin A (P¼0.0001) and cyclin B1 (P¼0.0004). There was no evidence of an increase in the LF for any phase
marker. Immunohistochemistry can be used to estimate cell cycle state and phase in laryngeal biopsies. Our data argues against
primary cell cycle phase abnormalities in laryngeal neoplasia.
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Squamous cell carcinoma of the larynx is the most common
neoplasm of the head and neck (Watkinson et al, 2000). Its
progression follows a series of steps through increasing grades of
dysplasia to malignancy (Shanmugaratnam, 1991). Despite an
understanding of this sequential process, little clarity exists as to
the precise histopathological distinction between different grades
of dysplasia. Moreover, algorithms for the management of
laryngeal malignancy do not adequately take into account the
biological aggressiveness of a lesion, which can result in small early
tumours recurring many times despite an apparently comprehen-
sive treatment protocol (Gale et al, 2000). Features predictive of
tumour aggression and poor ultimate survival are not consistently
demonstrated on histopathological evaluation (Gale et al, 2000),
giving rise to an inevitable degree of subjectivity and variability in
diagnosis (Hellquist et al, 1999). Given the potentially mutilating
and functionally disabling nature of aggressive laryngeal surgical
interventions, a drive towards earlier detection and more reliable
stratification of laryngeal dysplastic and malignant lesions would
be welcome and indeed is essential if further attempts to improve
quality of life and outcome are to be realised (Chatrath et al, 2003).
Estimation of cell cycle phase can be used to predict clinical
behaviour and response to chemotherapy in a variety of
malignancies (Huuhtanen et al, 1999; Sandquist et al, 2000;
Pelletier et al, 2001). Flow cytometry is a widely described
technique to analyse cell cycle phase in tumour tissue (Baretton
et al, 1990; Hixon et al, 1995; Nakamura et al, 1995; Pinto et al,
1997; Cascinu et al, 1998; Villanacci et al, 1998), but this approach
has not entered routine clinical practice. Reasons for this include a
lack of standardised procedures, difficulties in data interpretation,
tissue heterogeneity and complexity of the equipment required for
analysis. We aim to develop a simple immunohistochemical
method to allow cell cycle phase studies to be performed on
routine paraffin-embedded laryngeal tissue, using methods that we
have already demonstrated to be effective in colorectal tissue (Scott
et al, 2003).
To achieve this, we have utilised a panel of antibodies against
proteins involved in cell cycle regulation. These include mini-
chromosome maintenance protein 2 (Mcm-2) and Ki67, markers
of cell cycle entry and therefore cell cycle ‘state’ in tissues
(Maiorano et al, 1996; Newlon, 1997; Kearsey and Labib, 1998;
Musahl et al, 1998; Tanaka and Diffley, 2002). Minichromosome
maintenance protein 2 is one of six MCM proteins (MCMs 2–7)
that assemble in the prereplication complex and are essential for
DNA replication in eukaryotic cells (Kearsey and Labib, 1998). All
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ssix proteins are abundant throughout the cell cycle but are broken
down rapidly on differentiation and more slowly in quiescence
(Musahl et al, 1998). Antibodies against Mcm-2 have previously
been shown to detect more cycling cells in laryngeal tissues than
other ‘proliferation’ markers such as Ki67 (Chatrath et al, 2003),
and immunohistochemical staining for Mcm-2 and/or Mcm-5 has
been shown to be of value in identifying malignant or
premalignant lesions in a range of clinical specimens (Williams
et al, 1998; Freeman et al, 1999; Davies et al, 2002; Going et al,
2002; Chatrath et al, 2003; Scott et al, 2003; Sirieix et al, 2003; Scott
et al, 2004).
Other proteins detected in our method include putative markers
of cell cycle phase, levels of which peak during specific stages of
the cell cycle, followed by rapid degeneration as the cell progresses
to the next phase (Hunter and Pines, 1991; Hunter and Pines, 1994;
Musahl et al, 1998). These include cyclin D1, which is maximally
expressed in mid-to-late G1-phase and, together with cyclin E, is
involved in the G1 to S transition (Pines and Hunter, 1989). Cyclin
A is expressed in S-phase with variable expression in G2-phase
(Pines and Hunter, 1989; Sherr, 1996). Cyclin B1 is expressed as a
cytoplasmic molecule in G2-phase but becomes nuclear in early M,
until breakdown in early G1-phase (Nasmyth, 1996; Sherr, 1996).
Histone H3 is phosphorylated maximally in mitosis and phospho-
histone H3 is not detected following entry into G1-phase (Shibata
and Ajiro, 1993). Antibodies against these markers might therefore
enable in situ labelling of cells at all phases of the cell cycle, with
the exception of early G1 for which no useful marker is available
(Scott et al, 2003). Indeed, we have shown previously that in
colorectal mucosa, only small numbers of epithelial cells coexpress
putative markers of adjacent cell cycle phases and that the cell
cycle phase distribution determined by our immunohistochemical
approach compares well with phase analyses obtained by flow
cytometry (Scott et al, 2003).
Here, we demonstrate that our approach can be applied to
laryngeal dysplasia and SCC. Our data suggests that there are no
primary cell cycle phase abnormalities in these conditions.
Selected markers, particularly those of cell cycle entry, may
ultimately prove of value in improving the clinical management of
laryngeal neoplasia.
MATERIALS AND METHODS
Clinical specimens
Archival blocks of paraffin embedded, formalin-fixed human
laryngeal tissue, obtained from surgical resection specimens, were
retrieved in accordance with Local Research Ethics Committee
guidelines.
The tissues examined represented normal laryngeal squamous
epithelium taken from resection margins distant from tumour
(n¼8), various grades of laryngeal dysplasia (n¼10) and
laryngeal squamous cell carcinoma (SCC) (n¼10). The dysplastic
lesions were classified according to the Ljubljana classification
(Hellquist et al, 1999): seven represented atypical hyperplasia (low-
grade) and three carcinoma in situ (high-grade). None of the
patients with SCC had received preoperative neoadjuvant therapy.
Of the SCCs, four were well differentiated and six were moderately
differentiated.
Primary antibodies
We used mouse monoclonal antibodies against Mcm-2 (Mukherjee
et al, 2001, dilution 1:10); Ki67, (DAKO, Ely, UK Mib-1 clone,
dilution 1:10); Cyclin A, (Novocastra, Newcastle, UK, clone NCL
Cyclin A, dilution 1:20); Cyclin D1, (Novocastra, Newcastle, UK,
clone NCL Cyclin D1, dilution 1:50) and Cyclin B1, (DAKO, Ely,
UK, clone V152, dilution 1:400), and a rabbit polyclonal against
phosphohistone H3 (Upstate Biotechnology, Lake Placid, NY, USA,
ref 06-570, dilution 1:300).
Immunohistochemical staining of paraffin-embedded
tissues
Sections (5mm) were cut onto aminopropyltriethoxysilane (APES)
coated slides and processed for immunohistochemisty as described
previously (Freeman et al, 1999). Antigen retrieval was achieved by
pressure-cooking for 3min in citrate buffer (pH 6.0), except for the
cyclin D1 preparations, which required heating in a programmable
microwave (MicroMED T/T Mega) for 30min at 981C.
Primary antibody (100ml) was applied in a humidified chamber
at 41C overnight with gentle shaking in 1% BSA/TBS with 0.1%
Triton X-100. The slides were then washed in TBS containing
0.025% Triton X-100 and incubated for 1h with biotinylated goat
anti-mouse or goat anti-rabbit secondary antibody (DAKO, Ely,
UK). A streptavidin-horseradish peroxidase system (DAKO, Ely,
UK) with the substrate diaminobenzidine was used to develop the
stain. The slides were then lightly counterstained with Harris’
haematoxylin, dehydrated in increasing concentrations of alcohol
and cleared in xylene. Coverslips were applied with DEPEX
mounting medium (Gurr, BDH, Poole, Dorset, UK).
Negative controls were performed by omitting the primary
antibody or using isotype-matched negative control antibodies
(DAKO, Ely, UK). Sections of cervix showing various grades of
intraepithelial neoplasia were used as positive controls (Freeman
et al, 1999).
Double labelling studies
Double labelling experiments were performed as described
previously (Scott et al, 2003). For these studies we selected blocks
of SCC (n¼6), in which there were adjacent areas showing
dysplasia and normal laryngeal epithelium. Serial sections were
used to validate the results from each antibody combination.
Briefly, in the first series of reactions, antibody against Mcm-2 or
Ki67 was combined with each of four putative phase markers,
cyclin D1, cyclin A, cyclin B1 and phosphohistone H3. We tested
the hypothesis that if Mcm-2 identifies all cells in cycle, none of the
cyclin or phosphohistone H3 antibodies should detect cells
negative for Mcm-2. Similar considerations would apply to Ki67
as a potential marker of cycling cells.
The second series of reactions was designed to investigate the
frequency of coexpression of the putative markers of cell cycle
phase. Markers were paired as follows: phosphohistone H3-cyclin
D1 (putative markers of mitosis and G1-phase); cyclin D1-cyclin A
(G1-phase and S-phase); cyclin A-cyclin B1 (S-phase and G2-
phase); cyclin B1-phosphohistone H3 (G2-phase and mitosis).
Where the primary antibodies had been raised in different
species they were added together and incubated overnight.
Following washing, both secondary antibodies (Alexa Fluro goat
anti-mouse 488 and Alexa Fluro goat anti-rabbit 546; Molecular
Probes) were added together and incubated for one hour. After
further washing, slides were counterstained using 4,6-diamidino-
2-phenylindole (DAPI) (Sigma), washed and mounted in fluor-
escent mounting medium (DAKO).
When the primary antibodies were both mouse monoclonals a
different procedure was performed. Initially, one of the primary
antibodies was applied alone. After washing, the sections were
incubated with Alexa Fluro goat anti-mouse 488 (Molecular
Probes), followed by a blocking step with F(ab)2 goat anti-mouse
IgG fragments (Jackson Immuno Research Laboratories). A further
washing step was then performed before incubation with the
second primary antibody. Following a final washing step and
incubation in Alexa Fluro goat anti-mouse 633 (Molecular Probes),
the slides were counterstained and mounted as described above.
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confocal microscope at wavelengths of 488, 546 and 633nm.
Quantification of antibody staining
A quantitative indication of staining was determined for each
marker by calculating the percentage of total epithelial cells that
were immunopositive, to produce a labelling index (LI). In each
case a minimum of 500 cells was evaluated. Staining intensity was
not included in the assessment, as only relatively minor variations
in staining intensity were observed. The LI for each cell phase
marker was also expressed as a percentage of the number of Mcm-
2-positive cells, to produce a labelling fraction (LF). Labelling
fractions were determined to estimate the proportions of cells in
cycle that were in each cell-cycle phase. Approximations of the
percentage of cycling cells in S-phase, G2-phase and M-phase were
derived from the cyclin A LF, the cyclin B1 LF and the
phosphohistone H3 LF respectively.
Counts were repeated independently by three individual
observers (PC, ISS, RJD) and in all cases an inter-observer
variation of less than 5% was observed.
Statistical analysis
Differences between Mcm-2 and Ki67 LIs were compared using the
Bland and Altman limits of agreement analysis (Bland and Altman,
1999). Spearman’s rank correlation coefficient (r) and its 95%
confidence interval was used for correlation. Differences in the LIs
and LFs for each marker on progressing from normal through
dysplasia to SCC were assessed using the Jonckheere-Terpstra
(J–T) test (Hodges and Lehmann, 1963). Pairwise comparisons
from these data were made by comparison of the median values.
All analyses were carried out in SPSS V11.0 (SPSS inc, Chicago,
Illinois) and graphs plotted in SPSS and S-Plus 2000 (Mathsoft,
Seattle, WA).
RESULTS
Expression of Mcm-2 and Ki67
In the normal larynx, Mcm-2 expression was confined to the basal
layers of the epithelium, with the surface epithelium failing to show
any Mcm-2 expression, as described previously (Chatrath et al,
Normal larynx Laryngeal carcinoma in situ Laryngeal SCC
Cyclin D1
Cyclin A 
Cyclin B1
Phosphohistone
H3
100 m 100 m 100 m
100 m 100 m 100 m
100 m 100 m 100 m
100 m 100 m 100 m
Figure 1 Distribution of putative cell cycle phase markers in laryngeal epithelium. Immunohistochemical staining showing the distribution (from top to
bottom) of cyclins D1, A and B1 and phosphohistone H3 in normal larynx (left column), laryngeal carcinoma in situ (middle column) and laryngeal squamous
cell carcinoma (right column).
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expression was confined to the lower third. In contrast, in lesions
showing carcinoma in situ (high-grade), Mcm-2 was expressed
throughout the epithelium. The distribution of Ki67 was the same
as that of Mcm-2 (Chatrath et al, 2003) and there was a positive
correlation between Mcm-2 and Ki67 LIs (r¼0.93 (0.84, 0.97)).
However, Bland and Altman limits of agreement analysis of the
data for all three sample groups showed that Mcm-2 LIs were
consistently greater than Ki67 LIs. The mean difference was 17.49,
with limits of agreement of 1.59 (95% CI:  3.29, 6.97) and 33.40
(95% CI: 28.02, 38.77). The SCCs showed a median Mcm-2 LI of
82% (range 64–91) and a median Ki67 LI of 61% (range 42–89)
(Chatrath et al, 2003). In keeping with our findings at other
anatomical sites (Freeman et al, 1999), the highest LI values were
observed in the less well differentiated SCCs.
Expression of putative phase markers
Cyclin D1 The cyclin D1 LI increased on progression from
normal (median¼8.8%). through dysplasia (all cases; 11.4%) to
SCC (33.3%) (P¼0.015; J–T test). In all lesions, the distribution
was similar to that of Mcm-2 (Figure 1).
Cyclin A The tissue distribution of cyclin A was also similar to
that of Mcm-2. In atypical hyperplasia, cyclin A was expressed in
the basal and middle thirds of the epithelium, with full thickness
expression in carcinoma in situ (Figure 1). In the SCCs, staining
was seen throughout, but appeared to be greatest at the infiltrative
tumour edges. The cyclin A LI showed a significant increase on
progression from normal laryngeal epithelium (11.3%), through
dysplasia (25.1%) to malignancy (27.5%) (P¼0.0001; J–T test).
Cyclin B1 The staining pattern of cyclin B1 was either cytoplasmic,
consistent with the identification of cells in G2-phase, or diffuse,
consistent with M-phase. Labelling fractions were determined for
cytoplasmic B1 staining only: these increased on progression from
normal larynx (3.3%), through increasing grades of dysplasia (6.2%)
to SCC (13.3%) (P¼0.0004; J–T test). In the normal larynx, cyclin
B1 expression was largely confined to the basal third of the
epithelium (Figure 1) but with increasing grade of dysplasia,
expression expanded to involve the full thickness of the epithelium
(Figure 1). In SCC, staining was widespread (Figure 1).
Phosphohistone H3 Phophohistone H3 was detected in mitotic
figures and in occasional nuclei presumed to be in prophase
Mcm-2 (Green) and Ki67 (Red) Mcm-2 (Red) and cyclin D1 (Green)
Mcm-2 (Green) cyclin A (Red) Mcm-2 (Red) and cyclin B1 (Green)
AB
CD
Figure 2 Double labelling fluorescent confocal microscopy analysis of markers coexpressed with Mcm-2 or Ki67. (A) Mcm-2 (green) and Ki67 (red) in
normal laryngeal epithelium. Many cells coexpressed Mcm-2 and Ki67 (yellow), but occasional cells showed Mcm-2 expression in the absence of Ki67
(arrow). No cells showed Ki67 expression in the absence of Mcm-2. (B) Mcm-2 (red) detected all cells in a SCC coexpressing cyclin D1 (green), these cells
appearing yellow (arrow). (C) Mcm-2 (green) was expressed in all cells expressing cyclin A (red) in a SCC. The cells expressing Mcm-2 in the absence of
cyclin A appeared green. (D) In a SCC, nuclear Mcm-2 (red) was seen in cells showing cytoplasmic staining for cyclin B1 (green).
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was detected between normal larynx (0.4%), dysplastic larynx
(3.3%) through to squamous cell carcinoma (1.3%) (P¼0.29; J–T
test).
Analysis of the coexpression of cell cycle markers by
confocal microscopy
Double fluorescence labelling was first used to compare Mcm-2
expression with that of Ki67 (Figure 2A). While many cells
coexpressed Mcm-2 (green) and Ki67 (red) giving a yellow signal,
other cells showed Mcm-2 expression in the absence of Ki67. In
view of the detailed counting performed on the numerous sections
stained by immunohistochemistry (see above and below), formal
quantification of staining in the confocal images was not
performed. Nevertheless, in both SCC and normal laryngeal
epithelium approximately 70–80% of Mcm-2-positive cells coex-
pressed Ki67, with the remainder being Ki67-negative. No cells
were identified that expressed Ki67 in the absence of Mcm-2. In
addition, in all six cases examined, Mcm-2 was detected in all cells
expressing one of the putative cell cycle phase markers cyclin D1
(Figure 2B), cyclin A (Figure 2C), cyclin B1 (Figure 2D) and
phosphohistone H3 (not shown). The percentages of Mcm-2-
positive cells expressing each marker were within the range of the
LFs calculated in the numerous sections stained by immuno-
histochemistry (see below).
We also performed double labelling to assess the degree of
coexpression of the putative phase markers (Figure 3). There was
virtually no coexpression of cyclin D1 and cyclin A in any sample
(Figure 3A), the occasional cell showing coexpression presumably
being at the G1/S transition. In normal larynx and dysplastic
lesions there was coexpression of cyclin A and cytoplasmic cyclin
B1 in approximately 50% of cyclin A-positive cells (approximately
5–10% of cells overall), suggesting that immunodetectable
expression of cyclin A may extend further into G2 in laryngeal
epithelium than we have observed previously in the colon (Scott
et al, 2003) (Figure 3B). Many of the cells showing coexpression
demonstrated both a nuclear and cytoplasmic distribution of
cyclin A. In SCCs, however, coexpression of cyclin A and
cytoplasmic B1 was much less prominent, amounting to only
5–10% of cyclin A positive cells (2–3% of cells overall)
(Figure 3C). There was no colocalisation of nuclear cyclin B1
and cyclin A, suggesting that cyclin A expression is not detected in
cells entering mitosis (Figure 3C).
Cyclin D1 (Green) and cyclin A (Red) Cyclin A (Red) and cyclin B1 (Green)
Cyclin A (Red) and cyclin B1 (Green) Cyclin B1 (Green) and phosphohistone H3 (Red)
AB
CD
Figure 3 Double labelling fluorescent confocal microscopy analysis of coexpression of putative phase-specific markers. (A) There was negligible
coexpression of cyclin D1 and cyclin A. (B) In dysplasia there was focal coexpression of cytoplasmic cyclin B1 (green) and cyclin A (red), the latter showing a
nuclear and cytoplasmic distribution. An area of maximal coexpression is illustrated here. (C) In SCC, cytoplasmic cyclin B1 (green) was coexpressed by
relatively few cyclin A positive cells (red). (D) Rare cells in SCC (arrow) showed nuclear expression of phosphohistone H3 (red) plus cytoplasmic staining for
cyclin B1 (green), in keeping with cells at the G2/M transition.
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histone H3 (o5% of phosphohistone H3-positive cells), the
double-positive staining most likely representing cells in prophase
or early metaphase (Figure 3D).
Quantification of cycling cells
The LI values increased on progression from normal larynx
through laryngeal dysplasia to SCC for Mcm-2 (P¼0.001), Ki67
(P¼0.0002), cyclin D1 (P¼0.015), cyclin A (P¼0.0001), and
cyclin B1 (P¼0.0004) (Figure 4).
The frequency of expression of each putative phase marker was
determined as a percentage of the number of Mcm-2-positive cells
to produce a LF (Figure 5). There was no evidence of a difference
in the LFs for cyclin D1 (P¼0.33), cyclin A (P¼0.15), cyclin B1
(P¼0.11) or phosphohistone H3 (P¼0.48) on progressing from
normal larynx, through dysplasia to malignancy (J–T test).
DISCUSSION
An accurate description of cell cycle parameters may be important
in predicting the rate of growth, prognosis and response to
chemoradiotherapy in laryngeal SCC, thereby complementing
existing treatment protocols (Wilson et al, 2002). To achieve this
by means of an immunohistochemical technique would represent a
substantial advance, given the difficulties of flow cytometry in
routine diagnostic practice. Flow cytometry is impractical for large
scale analysis of laryngeal lesions, as biopsies are frequently only a
few millimetres in size. Operator dependency and difficulties in
standardisation between centres are also recognised problems.
Nuclear integrity from paraffin sections is variable and the
presence of inflammatory cellular infiltrates and blood vessels
distort the analysis by the addition of large numbers of cells with a
normal DNA complement. Aneuploid malignant cells may also
result in an overestimation of the fraction of cells in G2/M
(Monasebian and Ruskin, 1994).
Despite these technical limitations, there is some evidence that
estimation of S-phase fraction by flow cytometry can predict the
biological aggressiveness of tumours of the pharynx and larynx
(Mohr et al, 1992; Monasebian and Ruskin, 1994; Stern et al, 1995;
Wong et al, 1996; Myers et al, 1999). Hence, establishing a tool for
estimating S-phase fraction in tissue sections may be of potential
utility in improving diagnostic and treatment protocols for head
and neck tumours in general, and possibly in monitoring the
effectiveness of therapy. While alternative methods for measuring
expression of cell cycle markers exist, including analysis of
messenger RNA levels by microarray or quantitative PCR
techniology, demonstration of protein levels by immuno-
histochemistry is likely to be most informative and most
acceptable to general diagnostic laboratories.
In the present study, we did not compare our immunohisto-
chemical data with that obtained by flow cytometry on the same
samples. However, our overall technique has previously been
validated in surgical resection specimens of colorectal carcinoma
and ovarian neoplasms, in which we showed that our immuno-
histochemical model resulted in comparable cell cycle phase
analyses to those obtained by flow cytometry (Scott et al, 2003;
Scott et al, 2004). Nevertheless, confirmation of these observations
by parallel flow cytometric and immunohistochemical analysis of
laryngeal tumours will be important before commencing appro-
priately powered prognostic/predictive studies of larger numbers
of samples.
Our present results show that Mcm-2 is expressed in a greater
proportion of normal and neoplastic laryngeal epithelial cells than
Ki67, consistent with previous data (Chatrath et al, 2003). Our
findings suggest that whereas Ki67 can be expressed by cells in all
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Figure 4 Labelling indices for putative cell cycle phase markers. Dot plot
of cell cycle phase marker LIs in normal larynx (control), laryngeal dysplasia
(dysplasia), and laryngeal squamous cell carcinoma (cancer). The LIs
increased on progression from normal larynx through dysplasia to
squamous cell carcinoma for cyclin D1 (P¼0.015; J–T test), cyclin A
(P¼0.0001; J–T test), and cyclin B1 (P¼0.0004; J–T test). There was no
evidence of an increase in the LI for phosphohistone H3 (P¼0.29; J–T
test). Circles¼individual values. Bar¼median value.
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Figure 5 Labelling fractions for putative cell cycle phase markers in
normal laryngeal epithelium (normal), laryngeal dysplasia and laryngeal
squamous cell carcinoma (cancer). The frequencies of expression of
putative cell cycle phase markers are depicted as a percentage of the
number of Mcm-2-positive cells, to produce a LF. There was no evidence
of an increase in LFs for any of the markers shown.
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each phase and may therefore be less useful as a marker of cell
cycle state than MCMs. Detailed analysis by double-labelling
confocal microscopy suggests that the putative cell cycle phase-
specific markers investigated in this study do not show substantial
coexpression in laryngeal tissue, unlike findings in some tumour
lines (Pines and Hunter, 1989; Nasmyth, 1996). The apparent
phase-restricted expression of cyclin D1 suggests that previous
observations of its expression throughout the cell cycle in tumour
cell lines may not be reflected in vivo (Sherr, 1996). Alternatively,
the limitations of immunohistochemistry in terms of sensitivity
may restrict detection of cyclin D1 in situ to cells in mid-to-late G1,
when its expression is maximal (Nasmyth, 1996). It is noteworthy
that several antibodies recognising cyclin D1 are available and
these may stain different proportions of cells in immunohisto-
chemical preparations.
Cyclin A expression demonstrated minimal overlap with the
expression of cyclin D1, as a putative marker of G1-phase. The
degree of coexpression of cyclin A and cyclin B1 (a putative
marker of G2-phase) was greater than we observed in our previous
study of colorectal samples (Scott et al, 2003), although such
coexpression was less prominent in laryngeal SCC than in
dysplastic and normal laryngeal tissue. Previous analysis of
colorectal cancer showed that cyclin A was not detected in any
cell that was not actively replicating DNA (Scott et al, 2003),
leading us to suggest that immunohistochemically detectable
cyclin A expression could be used as a surrogate marker of
S-phase in paraffin-embedded tissue.
Progression from normal laryngeal epithelium through dyspla-
sia to SCC was associated with an increase in the LIs for each
putative phase-specific marker other than phosphohistone H3,
while the LFs remained consistent. These findings indicate that
there is no evidence for any phase-specific cell cycle abnormality
during neoplastic progression in laryngeal squamous epithelium.
The particular elevation of cyclin A LI that we observed in
laryngeal dysplasia is of uncertain significance, as no increase in
cyclin A LF was seen in the same samples. Reassessment of this
observation in a different, larger sample set is now required.
The immunohistochemical method used in this study offers
numerous practical benefits. Unlike flow cytometry, examination
of multiple sites from the available pathological specimen is
possible, thereby allowing for a more representative evaluation of
the inevitable heterogeneity that exists in laryngeal neoplasms. In
particular, it is possible to identify and analyse the high-grade,
poorly differentiated areas that are likely to exert the greatest
influence on outcome. While our method may not be applicable to
the very smallest samples, our experience to date is that an
adequate number of sections can be obtained from laryngeal
biopsies. Should larger scale studies confirm the present data, it
will be of great interest to investigate the value of MCMs and other
cell cycle markers in predicting prognosis and response to
chemoradiotherapy regimes in laryngeal dysplasia and malig-
nancy. The ease and reproducibility of the technique that we
describe would enable such work to be performed in most
diagnostic histopathology laboratories.
ACKNOWLEDGEMENTS
This study was funded by the Medical Research Council and
Cancer Research UK. We thank John Brown and Pamela Stacey for
technical assistance. Funding: Medical Research Council & Cancer
Research UK.
REFERENCES
Baretton G, Gille J, Oevermann E, Lohrs U (1990) Retrospective flow-
cytometric analysis of the DNA content in colorectal carcinomas and the
test of the prognostic significance of DNA ploidy. Verh Dtsch Ges Pathol
74: 233–237
Bland JM, Altman DG (1999) Measuring agreement in method comparison
studies. Stat Methods Med Res 8: 135–160
Cascinu S, Ligi M, Graziano F, Del Ferro E, Valentini M, Grianti C,
Bartolucci M, Catalano G (1998) S-phase fraction can predict event free
survival in patients with pT2-T3N0M0 colorectal carcinoma: implications
for adjuvant chemotherapy. Cancer 83: 1081–1085
Chatrath P, Scott IS, Morris LS, Davies RJ, Rushbrook SM, Bird K, Vowler
SL, Grant JW, Saeed IT, Howard D, Laskey RA, Coleman N (2003)
Aberrant expression of minichromosome maintenance protein-2 and
Ki67 in laryngeal squamous epithelial lesions. Br J Cancer 89: 1048–1054
Davies RJ, Freeman A, Morris LS, Bingham S, Dilworth S, Scott I, Laskey
RA, Miller R, Coleman N (2002) Analysis of minichromosome
maintenance proteins as a novel method for detection of colorectal
cancer in stool. Lancet 359: 1917–1919
Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH,
Coleman N (1999) Minichromosome maintenance proteins as biological
markers of dysplasia and malignancy. Clin Cancer Res 5: 2121–2132
Gale N, Kambic V, Michaels L, Cardesa A, Hellquist H, Zidar N, Poljak M
(2000) The Ljubljana classification: a practical strategy for the diagnosis
of laryngeal precancerous lesions. Adv Anat Pathol 7: 240–251
Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, Williams GH (2002)
Aberrant expression of minichromosome maintenance proteins 2 and 5,
and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett’s
mucosa. Gut 50: 373–377
Hellquist H, Cardesa A, Gale N, Kambic V, Michaels L (1999) Criteria for
grading in the Ljubljana classification of epithelial hyperplastic laryngeal
lesions. A study by members of the Working Group on Epithelial
Hyperplastic Laryngeal Lesions of the European Society of Pathology.
Histopathology 34: 226–233
Hixon C, Furlong J, Silbergleit A (1995) Flow cytometry in colon cancer:
does flow cytometric cell cycle analysis help predict for short-term
recurrence in patients with colorectal carcinoma? J Natl Med Assoc 87:
803–806
Hodges JL, Lehmann EL (1963) Nonparametric Statistical Methods. New
York: John Wiley and Sons
Hunter T, Pines J (1991) Cyclins and cancer. Cell 66: 1071–1074
Hunter T, Pines J (1994) Cyclins and cancer. II: cyclin D and CDK
inhibitors come of age. Cell 79: 573–582
Huuhtanen RL, Blomqvist CP, Wiklund TA, Bohling TO, Virolainen MJ,
Tukiainen EJ, Tribukait B, Andersson LC (1999) Comparison of the Ki-67
score and S-phase fraction as prognostic variables in soft-tissue sarcoma.
Br J Cancer 79: 945–951
Kearsey SE, Labib K (1998) MCM proteins: evolution, properties and role in
DNA replication. Biochem Biophys Acta 1398: 113–136
Maiorano D, Van Assendelft GB, Kearsey SE (1996) Fission yeast cdc21, a
member of the MCM protein family, is required for onset of S phase and
is located in the nucleus throughout the cell cycle. EMBO J 15: 861–872
Mohr C, Molls M, Streffer C, Pelzer T (1992) Prospective flow cytometric
analysis of head and neck carcinomas. Prognostic relevance of DNA-
content and S-fraction. J Craniomaxillofac Surg 20: 8–13
Monasebian DM, Ruskin JD (1994) Flow cytometric analysis of squamous
cell carcinoma of the tongue. J Oral Maxillofac Surg 52: 574–578,
discussion 578–579
Mukherjee G, Freeman A, Moore R, Kumaraswamy Devi KU, Morris LS,
Coleman N, Dilworth S, Prabhakaran PS, Stanley MA (2001) Biologic
factors and response to radiotherapy in carcinoma of the cervix. Int J
Gynecol Cancer 11: 187–193
Musahl C, Holthoff HP, Lesch R, Knippers R (1998) Stability of the
replicative Mcm3 protein in proliferating and differentiating human
cells. Exp Cell Res 241: 260–264
Myers EN, Sampedro A, Alvarez C, Martinez J, Suarez C, Alonso-Guervos
M, de los Toyos JR (1999) Cell proliferation activity and kinetic profile in
Cell cycle phase analysis in laryngeal neoplasia
P Chatrath et al
320
British Journal of Cancer (2006) 95(3), 314–321 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthe prognosis and therapeutic management of carcinoma of the pharynx
and larynx. Otolaryngol Head Neck Surg 121: 476–481
Nakamura S, Goto J, Kitayama Y, Sheffield JP, Talbot IC (1995) Flow
cytometric analysis of DNA synthetic phase fraction of the normal
appearing colonic mucosa in patients with colorectal neoplasms. Gut 37:
398–401
Nasmyth K (1996) Viewpoint: putting the cell cycle in order. Science 274:
1643–1645
Newlon CS (1997) Putting it all together: building a prereplicative complex.
Cell 91: 717–720
Pelletier MP, Edwardes MD, Michel RP, Halwani F, Morin JE (2001)
Prognostic markers in resectable non-small cell lung cancer: a multi-
variate analysis. Can J Surg 44: 180–188
Pines J, Hunter T (1989) Isolation of a human cyclin cDNA: evidence for
cyclin mRNA and protein regulation in the cell cycle and for interaction
with p34cdc2. Cell 58: 833–846
Pinto AE, Chaves P, Fidalgo P, Oliveira AG, Leitao CN, Soares J (1997) Flow
cytometric DNA ploidy and S-phase fraction correlate with histopatho-
logic indicators of tumor behavior in colorectal carcinoma. Dis Colon
Rectum 40: 411–419
Sandquist M, Thorstenson S, Brudin L (2000) A comparison between flow
cytometric assessment of S-phase fraction and Nottingham histologic
grade as prognostic instruments in breast cancer. Breast Cancer Res
Treat 63: 11–15
Scott IS, Heath TM, Morris LS, Rushbrook SM, Bird K, Vowler SL, Arends
MJ, Coleman N (2004) A novel immunohistochemical method for
estimating cell cycle phase distribution in ovarian serous neoplasms:
implications for the histopathological assessment of paraffin-embedded
specimens. Br J Cancer 90: 1583–1590
Scott IS, Morris LS, Bird K, Davies RJ, Vowler SL, Rushbrook SM, Marshall
AE, Laskey RA, Miller R, Arends MJ, Coleman N (2003) A novel
immunohistochemical method to estimate cell cycle phase distribution in
archival tissue: implications for the prediction of outcome in colorectal
cancer. J Pathol 201: 187–197
Shanmugaratnam K (1991) Histological Typing of Tumours of the Upper
Respiratory Tract and Ear. Berlin: Springer-Verlag
Sherr CJ (1996) Cancer Cell Cycles. Science 274: 1672–1677
Shibata K, Ajiro K (1993) Cell cycle-dependent suppressive effect of histone
H1 on mitosis-specific H3 phosphorylation. J Biol Chem 268: 18431–
18434
Sirieix P, O’Donovan M, Brown J, Save V, Coleman N, Fitzgerald R (2003)
Surface expression of minichromosome maintenance proteins provides
a novel method for detecting patients at risk for developing adeno-
carcinoma in Barrett’s oesophagus. Clin Cancer Res 9: 2560–2566
Stern Y, Aronson M, Shpitzer T, Nativ O, Medalia O, Segal K, Feinmesser R
(1995) Significance of DNA ploidy in the treatment of T1 glottic
carcinoma. Arch Otolaryngol Head Neck Surg 121: 1003–1005
Tanaka S, Diffley JF (2002) Interdependent nuclear accumulation of budding
yeast Cdt1 and Mcm2-7 during G1 phase. Nat Cell Biol 4: 198–207
Villanacci V, Grigolato PG, Cadei M, Cestari R, Ravelli P, Missale G (1998)
Flow cytometry study of DNA and cell kinetics in the adenoma –
carcinoma sequence in the large intestine. Pathologica 90: 120–126
Watkinson JC, Gaze JCW, Wilson JA (2000) Tumours of the Larynx. In Stell
& Maran’s Head & Neck Surgery Watkinson JC, Gaze MN & Wilson JA
(eds) pp. 233–275. Oxford: Butterworth-Heinemann
Williams GH, Romanowski P, Morris L, Madine M, Mills AD, Stoeber K,
Marr J, Laskey RA, Coleman N (1998) Improved cervical smear
assessment using antibodies against proteins that regulate DNA
replication. Proc Natl Acad Sci USA 95: 14932–14937
Wilson JA, Bradley P, Clark LC, Watkinson J, Wight R, Parker A, Robson A,
McKenzie K, Cox G, Welch A (2002) Effective Head and Neck Cancer
Management, Third Consensus Document 2002. In British Association of
Otorhinolaryngologists Head and Neck Surgeons (BAO-HNS). Document
6, Autumn 2002. London, UK: BAO-HNS
Wong G, Stidley C, Dressler L, Castillo M, Crooks L, Bartow S (1996)
Predictive value of flow cytometric analysis in DNA contents in patients
with locally advanced head and neck carcinoma. J Laryngol Otol 110:
243–248
Cell cycle phase analysis in laryngeal neoplasia
P Chatrath et al
321
British Journal of Cancer (2006) 95(3), 314–321 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s